

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EXPECTED INCREASE IN PROFIT FOR
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH (GROUP) CO., LTD.
FOR THE YEAR ENDED 31 DECEMBER 2023**

The board of directors (the “**Board**”) of MicroPort Scientific Corporation (the “**Company**”, together with its subsidiaries (the “**Group**”)) wishes to inform shareholders and potential investors of the Company that, based on the information currently available to the management, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (“**EV MedTech**”) is expected to record an increase in its profit for the year ended 31 December 2023.

EV MedTech is owned as to 40.32% by the Company and its results are consolidated with the financial statements of the Company. The shares of EV MedTech are listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

For the year ended 31 December 2023, the operating revenue of EV MedTech is expected to be between RMB1,174.4155 million and RMB1,201.3105 million, representing an increase of between 31% and 34% as compared with 2022; net profit attributable to the equity owners of EV MedTech is expected to be between RMB474.6484 million and RMB492.4923 million, representing an increase of between 33% and 38% as compared with 2022; net profit attributable to equity owners of EV MedTech after deducting non-recurring gains or losses is expected to be between RMB430.6461 million and RMB453.3116 million, representing an increase of between 33% and 40% as compared with 2022.

In 2023, EV MedTech continued to experience rapid growth in product sales and terminal implantation with its new products Talos[®] Thoracic Stent Graft System and Fontus[®] Branched Surgical Stent Graft System having been admitted to over 300 hospitals and implanted in over 3,200 cases so far, and Reewarm[®] PTX Drug Balloon Dilation Catheter (0.035” series) have been admitted to hospitals since the fourth quarter of 2023.

With the intensifying effort in the promotion of new products and the number of hospital admissions further increases, EV MedTech expects a continuous growth in the implantation volume and sales of the new products in 2024.

Meanwhile, EV MedTech has been stepping up its efforts to promote its products in the overseas markets, and its overseas sales revenue has a year-on-year growth of more than 50% in 2023. Among them, Castor® Branched Aortic Stent-Graft and Delivery System has realized clinical application in 16 countries; Hercules® Low Profile Straight Tube Stent Graft and Delivery System has been clinically applied in 21 countries; Minos® Abdominal Aortic Stent Graft and Delivery System has realized clinical application in 19 countries; and Hercules® Balloon Dilation Catheter has been clinically applied in 8 countries.

In addition, EV MedTech currently has a rich product development pipeline and has made positive progress in fields including aortic and peripheral vascular intervention and peripheral vascular intervention for tumors, and expects to further enhance its competitiveness in the relevant markets in the future.

Shareholders and investors are reminded that the financial information of EV MedTech above was prepared in accordance with PRC accounting standards and are limited solely to the operation of EV MedTech and are unrelated to the other subsidiaries of the Group. Such information is unaudited and has not been reviewed by the auditors or the audit committee of the Company and does not (a) exclude intra-group transactions, (b) include all the business of the Group, and (c) represent or provide a full picture of the operation or status of the Group. **Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the securities of the Company.**

By order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 29 January 2024

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors of the Company are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors of the Company are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.